John B. Craig

732 total citations
28 papers, 546 citations indexed

About

John B. Craig is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, John B. Craig has authored 28 papers receiving a total of 546 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Molecular Biology and 4 papers in Surgery. Recurrent topics in John B. Craig's work include Cancer therapeutics and mechanisms (7 papers), Cancer Treatment and Pharmacology (4 papers) and Lung Cancer Research Studies (3 papers). John B. Craig is often cited by papers focused on Cancer therapeutics and mechanisms (7 papers), Cancer Treatment and Pharmacology (4 papers) and Lung Cancer Research Studies (3 papers). John B. Craig collaborates with scholars based in United States, Japan and Myanmar. John B. Craig's co-authors include Bayard L. Powell, John G. Kuhn, Susan H. Socher, A Oliff, D. Martínez, Hyman B. Muss, Earl A. Surwit, Vinay K. Malviya, David S. Alberts and P. Y. Liu and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and The American Journal of the Medical Sciences.

In The Last Decade

John B. Craig

27 papers receiving 518 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John B. Craig United States 10 180 147 126 113 78 28 546
Christine R. Culy 11 222 1.2× 197 1.3× 98 0.8× 117 1.0× 48 0.6× 15 790
Theodotis Papageorgiou Greece 15 255 1.4× 220 1.5× 194 1.5× 89 0.8× 30 0.4× 52 955
Masao Sekiya Japan 12 102 0.6× 100 0.7× 56 0.4× 74 0.7× 33 0.4× 41 437
Reto Cortesi Switzerland 6 253 1.4× 208 1.4× 36 0.3× 54 0.5× 33 0.4× 7 583
Ron Vergona United States 13 88 0.5× 138 0.9× 66 0.5× 76 0.7× 41 0.5× 17 734
Hélène Dulude Canada 16 193 1.1× 134 0.9× 160 1.3× 184 1.6× 42 0.5× 37 798
D Cirillo Italy 13 95 0.5× 185 1.3× 60 0.5× 35 0.3× 87 1.1× 30 631
Daniel P. Nadeau United States 11 124 0.7× 346 2.4× 70 0.6× 33 0.3× 68 0.9× 13 736
Tatsuya Mori Japan 13 60 0.3× 79 0.5× 219 1.7× 104 0.9× 58 0.7× 49 601
Daniel M. Lane United States 15 103 0.6× 113 0.8× 134 1.1× 73 0.6× 29 0.4× 28 707

Countries citing papers authored by John B. Craig

Since Specialization
Citations

This map shows the geographic impact of John B. Craig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John B. Craig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John B. Craig more than expected).

Fields of papers citing papers by John B. Craig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John B. Craig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John B. Craig. The network helps show where John B. Craig may publish in the future.

Co-authorship network of co-authors of John B. Craig

This figure shows the co-authorship network connecting the top 25 collaborators of John B. Craig. A scholar is included among the top collaborators of John B. Craig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John B. Craig. John B. Craig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vokes, Everett E., Richard K. Rosenberg, Mohammad Jahanzeb, et al.. (1995). Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer.. Journal of Clinical Oncology. 13(3). 637–644. 34 indexed citations
2.
Malviya, Vinay K., P. Y. Liu, Robert V. O’Toole, et al.. (1994). Phase II Trial of Amonafide in Patients with Advanced Metastatic or Recurrent Endometrial Adenocarcinoma A Southwest Oncology Group Study. American Journal of Clinical Oncology. 17(1). 37–40. 9 indexed citations
3.
Marshall, M. Ernest, Brent A. Blumenstein, E. David Crawford, et al.. (1994). Phase II Trial of Amonafide for the Treatment of Advanced, Hormonally Refractory Carcinoma of the Prostate. American Journal of Clinical Oncology. 17(6). 514–515. 16 indexed citations
4.
Rodriguez, Gladys, Thomas D. Brown, Frank M. Balis, et al.. (1993). A phase I trial of trimetrexate (NSC352122) on a daily × 5 schedule in patients with refractory adult leukemia. Anti-Cancer Drugs. 4(2). 163–166. 3 indexed citations
5.
Brown, Thomas D., et al.. (1993). Phase II trial of amonafide in advanced colorectal cancer: a SouthWest Oncology Group study. Anti-Cancer Drugs. 4(1). 49–50. 2 indexed citations
6.
Slavik, Milan, Kenneth J. Kopecky, Vernon K. Sondak, John B. Craig, & Michael K. Samson. (1993). Evaluation of amonafide in disseminated malignant melanoma. Investigational New Drugs. 11(2-3). 223–226. 5 indexed citations
7.
Malviya, Vinay K., P. Y. Liu, David S. Alberts, et al.. (1992). Evaluation of Amonafide in Cervical Cancer, Phase II. American Journal of Clinical Oncology. 15(1). 41–44. 53 indexed citations
8.
Havlin, Kathleen A., John G. Kuhn, John B. Craig, et al.. (1991). Phase I evaluation of 773U82 HCI, a member of a new class of DNA intercalators. Anti-Cancer Drugs. 2(4). 357–364.
9.
Cobb, Patrick, Kathleen A. Havlin, John G. Kuhn, et al.. (1991). Phase I Evaluation of Crisnatol (BWA770U Mesylate) on a Monthly Extended Infusion Schedule. PubMed. 7(2). 85–91. 2 indexed citations
10.
Higano, Celestia S., Phyllis J. Goodman, John B. Craig, et al.. (1991). Phase II evaluation of amonafide in renal cell carcinoma. Investigational New Drugs. 9(4). 361–363. 7 indexed citations
11.
Jackson, Don V., John B. Craig, Charles L. Spurr, et al.. (1990). Vincristine Infusion with CHOP-CCNU in Diffuse Large-Cell Lymphoma. Cancer Investigation. 8(1). 7–12. 2 indexed citations
12.
Osborne, C. Kent, et al.. (1989). Phase II trial of a new biological response modifier (ImuVert) in advanced prostate cancer. Investigational New Drugs. 7(2-3). 243–245. 2 indexed citations
13.
Saez, Ruben A., John B. Craig, John G. Kuhn, et al.. (1989). Phase I clinical investigation of amonafide.. Journal of Clinical Oncology. 7(9). 1351–1358. 34 indexed citations
14.
Craig, John B., John G. Kuhn, Jay Luther, et al.. (1988). Phase I and clinical pharmacology trial of crisnatol (BWA770U mesylate) using a monthly single-dose schedule.. PubMed. 48(16). 4706–10. 12 indexed citations
15.
Powell, Bayard L., John B. Craig, Hyman B. Muss, et al.. (1988). Phase II Trial of High-Dose Cytosine Arabinoside and Cisplatin in Recurrent Squamous Carcinoma of the Head and Neck A Piedmont Oncology Association Study. American Journal of Clinical Oncology. 11(5). 550–552. 3 indexed citations
16.
Powell, Bayard L., et al.. (1988). Phase I–II trial of acivicin in adult acute leukemia. Investigational New Drugs. 6(1). 41–44. 6 indexed citations
17.
Socher, Susan H., D. Martínez, John B. Craig, John G. Kuhn, & A Oliff. (1988). Tumor Necrosis Factor Not Detectable in Patients With Clinical Cancer Cachexia. JNCI Journal of the National Cancer Institute. 80(8). 595–598. 110 indexed citations
18.
Hanauske, A.-R., Gary M. Clark, John B. Craig, et al.. (1988). Phase I clinical trial of carbetimer.. PubMed. 48(18). 5353–7. 7 indexed citations
19.
Powell, Bayard L. & John B. Craig. (1987). Review: Adjuvant Chemotherapy of Solid Tumors. The American Journal of the Medical Sciences. 294(1). 33–41. 2 indexed citations
20.
Powell, Bayard L., John B. Craig, & Hyman B. Muss. (1985). Secondary malignancies of the penis and epididymis: a case report and review of the literature.. Journal of Clinical Oncology. 3(1). 110–116. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christine R. Culy Breakdown of academic impact, for papers by Theodotis Papageorgiou Breakdown of academic impact, for papers by Masao Sekiya Breakdown of academic impact, for papers by Reto Cortesi Breakdown of academic impact, for papers by Ron Vergona Breakdown of academic impact, for papers by Hélène Dulude Breakdown of academic impact, for papers by D Cirillo Breakdown of academic impact, for papers by Daniel P. Nadeau Breakdown of academic impact, for papers by Tatsuya Mori Breakdown of academic impact, for papers by Daniel M. Lane
Rankless by CCL
2026